# A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

> **NCT06892288** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Glycomine, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Phosphomannomutase 2 Deficiency
- PMM2-CDG

## Interventions

- **DRUG:** GLM101 (Part A, Double-blind)
- **DRUG:** Placebo (Part A, Double-blind)
- **DRUG:** GLM101 (Part B, Open-label)

## Key facts

- **NCT ID:** NCT06892288
- **Lead sponsor:** Glycomine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892288, "A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06892288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*